The influence of lithium on fluvoxamine therapeutic efficacy and pharmacokinetics in depressed patients on combined fluvoxamine-lithium therapy
Само за регистроване кориснике
1997
Чланак у часопису (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт
The influence of lithium on fluvoxamine therapeutic efficacy, plasma concentrations and pharmacokinetics was studied in 12 depressed inpatients. Six patients were on fluvoxamine monotherapy and six were on combined fluvoxamine-lithium therapy. The treatment response was determined using 17-item Hamilton Rating Scale for Depression. Blood samples were collected during 48 h after a single dose administration of 100 mg fluvoxamine, and five times at steady state after repeated doses of 100 mg fluvoxamine per day. The evaluation of 17-item Hamilton Rating Scale for Depression Scores showed a significant clinical improvement 2 and 4 weeks after the beginning of the therapy in both groups (p lt 0.01). However, 2 weeks after the administration of the drug(s) had started, significant differences (p lt 0.05) in efficacy between the two treatments in favour of the fluvoxamine-lithium combination were found. Plasma concentrations of fluvoxamine were measured by high-performance liquid chromat...ography. The comparison of the measured concentrations of fluvoxamine showed a similar course of the plasma concentration-time curves in both groups of patients. Pharmacokinetic parameters of fluvoxamine did not show any significant difference on the comparison between the groups. According to the results from this study, it is evident that lithium does not affect plasma concentrations and pharmacokinetics of fluvoxamine in depressed patients on concomitant treatment with these two drugs. However, the effect achieved with the combination was better.
Кључне речи:
Depression / Fluvoxamine / Interaction / Lithium / PharmacokineticsИзвор:
International Clinical Psychopharmacology, 1997, 12, 4, 207-212Издавач:
- Rapid Science Publishers, London
DOI: 10.1097/00004850-199707000-00004
ISSN: 0268-1315
PubMed: 9347381
WoS: A1997XY01900004
Scopus: 2-s2.0-0030866016
Институција/група
PharmacyTY - JOUR AU - Miljković, Branislava AU - Pokrajac, Milena AU - Timotijević, Ivana AU - Varagić, V.M. PY - 1997 UR - https://farfar.pharmacy.bg.ac.rs/handle/123456789/155 AB - The influence of lithium on fluvoxamine therapeutic efficacy, plasma concentrations and pharmacokinetics was studied in 12 depressed inpatients. Six patients were on fluvoxamine monotherapy and six were on combined fluvoxamine-lithium therapy. The treatment response was determined using 17-item Hamilton Rating Scale for Depression. Blood samples were collected during 48 h after a single dose administration of 100 mg fluvoxamine, and five times at steady state after repeated doses of 100 mg fluvoxamine per day. The evaluation of 17-item Hamilton Rating Scale for Depression Scores showed a significant clinical improvement 2 and 4 weeks after the beginning of the therapy in both groups (p lt 0.01). However, 2 weeks after the administration of the drug(s) had started, significant differences (p lt 0.05) in efficacy between the two treatments in favour of the fluvoxamine-lithium combination were found. Plasma concentrations of fluvoxamine were measured by high-performance liquid chromatography. The comparison of the measured concentrations of fluvoxamine showed a similar course of the plasma concentration-time curves in both groups of patients. Pharmacokinetic parameters of fluvoxamine did not show any significant difference on the comparison between the groups. According to the results from this study, it is evident that lithium does not affect plasma concentrations and pharmacokinetics of fluvoxamine in depressed patients on concomitant treatment with these two drugs. However, the effect achieved with the combination was better. PB - Rapid Science Publishers, London T2 - International Clinical Psychopharmacology T1 - The influence of lithium on fluvoxamine therapeutic efficacy and pharmacokinetics in depressed patients on combined fluvoxamine-lithium therapy VL - 12 IS - 4 SP - 207 EP - 212 DO - 10.1097/00004850-199707000-00004 ER -
@article{ author = "Miljković, Branislava and Pokrajac, Milena and Timotijević, Ivana and Varagić, V.M.", year = "1997", abstract = "The influence of lithium on fluvoxamine therapeutic efficacy, plasma concentrations and pharmacokinetics was studied in 12 depressed inpatients. Six patients were on fluvoxamine monotherapy and six were on combined fluvoxamine-lithium therapy. The treatment response was determined using 17-item Hamilton Rating Scale for Depression. Blood samples were collected during 48 h after a single dose administration of 100 mg fluvoxamine, and five times at steady state after repeated doses of 100 mg fluvoxamine per day. The evaluation of 17-item Hamilton Rating Scale for Depression Scores showed a significant clinical improvement 2 and 4 weeks after the beginning of the therapy in both groups (p lt 0.01). However, 2 weeks after the administration of the drug(s) had started, significant differences (p lt 0.05) in efficacy between the two treatments in favour of the fluvoxamine-lithium combination were found. Plasma concentrations of fluvoxamine were measured by high-performance liquid chromatography. The comparison of the measured concentrations of fluvoxamine showed a similar course of the plasma concentration-time curves in both groups of patients. Pharmacokinetic parameters of fluvoxamine did not show any significant difference on the comparison between the groups. According to the results from this study, it is evident that lithium does not affect plasma concentrations and pharmacokinetics of fluvoxamine in depressed patients on concomitant treatment with these two drugs. However, the effect achieved with the combination was better.", publisher = "Rapid Science Publishers, London", journal = "International Clinical Psychopharmacology", title = "The influence of lithium on fluvoxamine therapeutic efficacy and pharmacokinetics in depressed patients on combined fluvoxamine-lithium therapy", volume = "12", number = "4", pages = "207-212", doi = "10.1097/00004850-199707000-00004" }
Miljković, B., Pokrajac, M., Timotijević, I.,& Varagić, V.M.. (1997). The influence of lithium on fluvoxamine therapeutic efficacy and pharmacokinetics in depressed patients on combined fluvoxamine-lithium therapy. in International Clinical Psychopharmacology Rapid Science Publishers, London., 12(4), 207-212. https://doi.org/10.1097/00004850-199707000-00004
Miljković B, Pokrajac M, Timotijević I, Varagić V. The influence of lithium on fluvoxamine therapeutic efficacy and pharmacokinetics in depressed patients on combined fluvoxamine-lithium therapy. in International Clinical Psychopharmacology. 1997;12(4):207-212. doi:10.1097/00004850-199707000-00004 .
Miljković, Branislava, Pokrajac, Milena, Timotijević, Ivana, Varagić, V.M., "The influence of lithium on fluvoxamine therapeutic efficacy and pharmacokinetics in depressed patients on combined fluvoxamine-lithium therapy" in International Clinical Psychopharmacology, 12, no. 4 (1997):207-212, https://doi.org/10.1097/00004850-199707000-00004 . .